Poly ICLC ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04544007 (ClinicalTrials.gov) | December 15, 2021 | 2/9/2020 | A Phase II Trial of Poly-ICLC for Low-Grade Gliomas | A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1 | NF1;Low-grade Glioma | Drug: Poly ICLC | University of Alabama at Birmingham | Children's Healthcare of Atlanta;Children's Hospital Los Angeles | Recruiting | N/A | 22 Years | All | 20 | Phase 2 | United States |